American Journal of Cardiology, The, ISSN 0002-9149, 2009, Volume 103, Issue 10, pp. 1467 - 1472
Although previous studies including endurance athletes after marathon running have demonstrated biochemical evidence of cardiac injury and have correlated...
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | BRAIN NATRIURETIC PEPTIDE | PROLONGED EXERCISE | OF-CARDIOLOGY | STRENUOUS EXERCISE | MASS | TROPONIN-T | MYOCARDIAL INJURY | ECHOCARDIOGRAPHY | VENTRICULAR DYSFUNCTION | EUROPEAN-SOCIETY | Echocardiography | Prospective Studies | Creatine Kinase - blood | Humans | Male | Biomarkers - blood | Physical Endurance - physiology | Magnetic Resonance Imaging | Running - physiology | Troponin - blood | Adult | Female | Ventricular Function, Right - physiology | Myoglobin - blood | Myoglobin | Magnetic resonance imaging | Creatine kinase | Athletes | Biological markers | Creatine | Marathon running
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | BRAIN NATRIURETIC PEPTIDE | PROLONGED EXERCISE | OF-CARDIOLOGY | STRENUOUS EXERCISE | MASS | TROPONIN-T | MYOCARDIAL INJURY | ECHOCARDIOGRAPHY | VENTRICULAR DYSFUNCTION | EUROPEAN-SOCIETY | Echocardiography | Prospective Studies | Creatine Kinase - blood | Humans | Male | Biomarkers - blood | Physical Endurance - physiology | Magnetic Resonance Imaging | Running - physiology | Troponin - blood | Adult | Female | Ventricular Function, Right - physiology | Myoglobin - blood | Myoglobin | Magnetic resonance imaging | Creatine kinase | Athletes | Biological markers | Creatine | Marathon running
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2017
Abstract Trans-catheter aortic valve implantation (TAVI) is the treatment of choice for inoperable and high risk patients with severe aortic stenosis. Our...
Cardiovascular
Cardiovascular
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 3, pp. 289 - 295
Background Chest pain is one of the most common reasons for presentation to the emergency department (ED); however, there is a paucity of data evaluating the...
Cardiovascular | CORONARY-HEART-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | OUTCOMES | Emergency Service, Hospital | Myocardial Infarction - epidemiology | Myocardial Infarction - mortality | Prognosis | Risk Assessment | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Continuity of Patient Care - organization & administration | Chest Pain - etiology | Chest Pain - mortality | Female | Aged | Chest Pain - diagnosis | Myocardial Infarction - prevention & control | Retrospective Studies | Physicians, Primary Care | Cardiology | Chest Pain - therapy | Physician's Role | Emergency service | Hospitals | Physicians | Chest pain | Heart attacks | Drug therapy | Patients | Clinical outcomes
Cardiovascular | CORONARY-HEART-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | OUTCOMES | Emergency Service, Hospital | Myocardial Infarction - epidemiology | Myocardial Infarction - mortality | Prognosis | Risk Assessment | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Continuity of Patient Care - organization & administration | Chest Pain - etiology | Chest Pain - mortality | Female | Aged | Chest Pain - diagnosis | Myocardial Infarction - prevention & control | Retrospective Studies | Physicians, Primary Care | Cardiology | Chest Pain - therapy | Physician's Role | Emergency service | Hospitals | Physicians | Chest pain | Heart attacks | Drug therapy | Patients | Clinical outcomes
Journal Article
American Heart Journal, ISSN 0002-8703, 2015, Volume 170, Issue 5, pp. 1018 - 1024.e2
Background β-Blocker therapy is one of the most commonly prescribed treatments for patients with cardiac conditions. In patients with out-of-hospital cardiac...
Cardiovascular | SURVIVAL | ARRIVAL | CARDIAC & CARDIOVASCULAR SYSTEMS | PRACTICE GUIDELINES | MANAGEMENT | TASK-FORCE | PROPENSITY SCORE METHODS | AMERICAN-COLLEGE | Cardiopulmonary Resuscitation - methods | Humans | Risk Factors | Male | Out-of-Hospital Cardiac Arrest - mortality | Treatment Outcome | Incidence | Out-of-Hospital Cardiac Arrest - therapy | Propensity Score | Ontario - epidemiology | Aged, 80 and over | Female | Aged | Retrospective Studies | Emergency Medical Services | Adrenergic beta-Antagonists - therapeutic use
Cardiovascular | SURVIVAL | ARRIVAL | CARDIAC & CARDIOVASCULAR SYSTEMS | PRACTICE GUIDELINES | MANAGEMENT | TASK-FORCE | PROPENSITY SCORE METHODS | AMERICAN-COLLEGE | Cardiopulmonary Resuscitation - methods | Humans | Risk Factors | Male | Out-of-Hospital Cardiac Arrest - mortality | Treatment Outcome | Incidence | Out-of-Hospital Cardiac Arrest - therapy | Propensity Score | Ontario - epidemiology | Aged, 80 and over | Female | Aged | Retrospective Studies | Emergency Medical Services | Adrenergic beta-Antagonists - therapeutic use
Journal Article
Journal of the American Society of Echocardiography, ISSN 0894-7317, 2009, Volume 22, Issue 4, pp. 418 - 424
Background Trastuzumab provides considerable therapeutic benefits in the adjuvant setting of breast cancer. However, its use is limited by an elevated...
Cardiovascular | Doppler tissue imaging | Cardiomyopathy | Doxorubicin | Myocet | Trastuzumab | ADJUVANT CHEMOTHERAPY | OXIDATIVE STRESS | CARDIAC & CARDIOVASCULAR SYSTEMS | CYCLOPHOSPHAMIDE | LIPOSOME-ENCAPSULATED DOXORUBICIN | REDUCED CARDIOTOXICITY | RECEPTOR | CONVENTIONAL DOXORUBICIN | PHASE-III TRIAL | MULTICENTER TRIAL | 1ST-LINE THERAPY | Anthracyclines - adverse effects | Risk Assessment - methods | Humans | Mice, Inbred C57BL | Risk Factors | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ventricular Dysfunction, Left - chemically induced | Ventricular Dysfunction, Left - diagnostic imaging | Dose-Response Relationship, Drug | Elasticity Imaging Techniques - methods | Antibodies, Monoclonal, Humanized | Animals | Antineoplastic Agents - adverse effects | Echocardiography, Doppler - methods | Mice | Doxorubicin - adverse effects | Index Medicus
Cardiovascular | Doppler tissue imaging | Cardiomyopathy | Doxorubicin | Myocet | Trastuzumab | ADJUVANT CHEMOTHERAPY | OXIDATIVE STRESS | CARDIAC & CARDIOVASCULAR SYSTEMS | CYCLOPHOSPHAMIDE | LIPOSOME-ENCAPSULATED DOXORUBICIN | REDUCED CARDIOTOXICITY | RECEPTOR | CONVENTIONAL DOXORUBICIN | PHASE-III TRIAL | MULTICENTER TRIAL | 1ST-LINE THERAPY | Anthracyclines - adverse effects | Risk Assessment - methods | Humans | Mice, Inbred C57BL | Risk Factors | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ventricular Dysfunction, Left - chemically induced | Ventricular Dysfunction, Left - diagnostic imaging | Dose-Response Relationship, Drug | Elasticity Imaging Techniques - methods | Antibodies, Monoclonal, Humanized | Animals | Antineoplastic Agents - adverse effects | Echocardiography, Doppler - methods | Mice | Doxorubicin - adverse effects | Index Medicus
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 2014, Volume 7, Issue 7, pp. 761 - 767
Objectives The aim of the study was to determine native coronary artery patency 1 year after coronary artery bypass grafting and to identify clinical and...
Cardiovascular | coronary artery disease | coronary artery bypass grafting | CARDIAC & CARDIOVASCULAR SYSTEMS | GRAFTS | ATHEROSCLEROSIS | RANDOMIZED-TRIAL | ANGIOGRAPHIC FOLLOW-UP | COMPETITIVE FLOW | SAPHENOUS-VEIN | RADIAL-ARTERY | ENDOTHELIAL SHEAR-STRESS | INTERNAL THORACIC ARTERY | IN-STENT RESTENOSIS | Coronary Vessels - diagnostic imaging | Predictive Value of Tests | Coronary Artery Disease - surgery | Saphenous Vein - transplantation | Coronary Vessels - physiopathology | Humans | Middle Aged | Male | Coronary Occlusion - diagnosis | Coronary Artery Disease - physiopathology | Time Factors | Radial Artery - transplantation | Female | Databases, Factual | Coronary Artery Bypass - methods | Risk Factors | Treatment Outcome | Coronary Angiography | Coronary Artery Bypass - adverse effects | Coronary Artery Disease - diagnosis | Coronary Occlusion - etiology | Coronary Vessels - surgery | Aged | Chronic Disease | Coronary Occlusion - physiopathology | Vascular Patency
Cardiovascular | coronary artery disease | coronary artery bypass grafting | CARDIAC & CARDIOVASCULAR SYSTEMS | GRAFTS | ATHEROSCLEROSIS | RANDOMIZED-TRIAL | ANGIOGRAPHIC FOLLOW-UP | COMPETITIVE FLOW | SAPHENOUS-VEIN | RADIAL-ARTERY | ENDOTHELIAL SHEAR-STRESS | INTERNAL THORACIC ARTERY | IN-STENT RESTENOSIS | Coronary Vessels - diagnostic imaging | Predictive Value of Tests | Coronary Artery Disease - surgery | Saphenous Vein - transplantation | Coronary Vessels - physiopathology | Humans | Middle Aged | Male | Coronary Occlusion - diagnosis | Coronary Artery Disease - physiopathology | Time Factors | Radial Artery - transplantation | Female | Databases, Factual | Coronary Artery Bypass - methods | Risk Factors | Treatment Outcome | Coronary Angiography | Coronary Artery Bypass - adverse effects | Coronary Artery Disease - diagnosis | Coronary Occlusion - etiology | Coronary Vessels - surgery | Aged | Chronic Disease | Coronary Occlusion - physiopathology | Vascular Patency
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2015, Volume 116, Issue 5, pp. 671 - 677
Although randomized studies have shown optimal medical therapy (OMT) to be as efficacious as revascularization in stable coronary heart disease (CHD), the...
Cardiovascular | REVASCULARIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | GUIDELINES | INTERVENTION | ASSOCIATION | ARTERY-DISEASE | Prognosis | Survival Rate - trends | Follow-Up Studies | Humans | Male | Treatment Outcome | Coronary Artery Disease - drug therapy | Incidence | Coronary Angiography | Coronary Artery Disease - diagnostic imaging | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Ontario - epidemiology | Cause of Death - trends | Female | Aged | Coronary Artery Disease - epidemiology | Retrospective Studies | Adrenergic beta-Antagonists - therapeutic use | Enzymes | Aspirin | Analysis | Mortality | Angiotensin | Diagnostic imaging | Coronary heart disease | Statins | Cardiovascular disease | Heart attacks | Angina pectoris | Cardiology | Clinical outcomes
Cardiovascular | REVASCULARIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | GUIDELINES | INTERVENTION | ASSOCIATION | ARTERY-DISEASE | Prognosis | Survival Rate - trends | Follow-Up Studies | Humans | Male | Treatment Outcome | Coronary Artery Disease - drug therapy | Incidence | Coronary Angiography | Coronary Artery Disease - diagnostic imaging | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Ontario - epidemiology | Cause of Death - trends | Female | Aged | Coronary Artery Disease - epidemiology | Retrospective Studies | Adrenergic beta-Antagonists - therapeutic use | Enzymes | Aspirin | Analysis | Mortality | Angiotensin | Diagnostic imaging | Coronary heart disease | Statins | Cardiovascular disease | Heart attacks | Angina pectoris | Cardiology | Clinical outcomes
Journal Article
Canadian Journal of Cardiology, ISSN 0828-282X, 2012, Volume 28, Issue 1, pp. 40 - 47
Abstract Background We examine the clinical characteristics and outcomes of ST-elevation myocardial infarction (STEMI) patients receiving various reperfusion...
Cardiovascular | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | PREHOSPITAL FIBRINOLYSIS | RISK STRATIFICATION | THROMBOLYSIS | MANAGEMENT-PRACTICES | HOSPITAL OUTCOMES | INTERVENTION | PRIMARY ANGIOPLASTY | BASE-LINE CHARACTERISTICS | Myocardial Infarction - epidemiology | Survival Rate - trends | Follow-Up Studies | Humans | Middle Aged | Male | Treatment Outcome | Disease Progression | Myocardial Reperfusion - methods | Patient Satisfaction | Myocardial Infarction - therapy | Canada - epidemiology | Thrombolytic Therapy - methods | Electrocardiography | Female | Myocardial Infarction - physiopathology | Registries | Retrospective Studies | Thrombolytic Therapy - standards | Myocardial Reperfusion - standards | Practice Guidelines as Topic
Cardiovascular | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | PREHOSPITAL FIBRINOLYSIS | RISK STRATIFICATION | THROMBOLYSIS | MANAGEMENT-PRACTICES | HOSPITAL OUTCOMES | INTERVENTION | PRIMARY ANGIOPLASTY | BASE-LINE CHARACTERISTICS | Myocardial Infarction - epidemiology | Survival Rate - trends | Follow-Up Studies | Humans | Middle Aged | Male | Treatment Outcome | Disease Progression | Myocardial Reperfusion - methods | Patient Satisfaction | Myocardial Infarction - therapy | Canada - epidemiology | Thrombolytic Therapy - methods | Electrocardiography | Female | Myocardial Infarction - physiopathology | Registries | Retrospective Studies | Thrombolytic Therapy - standards | Myocardial Reperfusion - standards | Practice Guidelines as Topic
Journal Article
American Heart Journal, ISSN 0002-8703, 05/2018, Volume 199, pp. 144 - 149
Although the burden of aortic stenosis (AS) on our health care system is expected to rise, little is known regarding its epidemiology at the population level....
MORTALITY | SURGERY | POPULATION | HIGH-RISK PATIENTS | CARDIAC & CARDIOVASCULAR SYSTEMS | IMPLANTATION | DISEASE | VALVE-REPLACEMENT | TEMPORAL TRENDS | ASSOCIATION | TRANSCATHETER | Risk Assessment - methods | Age Distribution | Prognosis | Survival Rate - trends | Follow-Up Studies | Humans | Risk Factors | Male | Aortic Valve Stenosis - therapy | Incidence | Aortic Valve Stenosis - epidemiology | Time Factors | Hospitalization - trends | Ontario - epidemiology | Sex Distribution | Female | Aged | Retrospective Studies | Population Surveillance - methods | Medical research | Mortality | Analysis | Aortic valve stenosis | Patient outcomes | Medicine, Experimental | Epidemiology | Health care | Elderly people | Intervention | Population growth | Stenosis | Cardiovascular disease | Hospitalization | Regression analysis | Patients | Clinical outcomes | Regression models | Morality | Coronary vessels | Aorta | Trends | Aortic valve | Elderly | Age | Geriatrics
MORTALITY | SURGERY | POPULATION | HIGH-RISK PATIENTS | CARDIAC & CARDIOVASCULAR SYSTEMS | IMPLANTATION | DISEASE | VALVE-REPLACEMENT | TEMPORAL TRENDS | ASSOCIATION | TRANSCATHETER | Risk Assessment - methods | Age Distribution | Prognosis | Survival Rate - trends | Follow-Up Studies | Humans | Risk Factors | Male | Aortic Valve Stenosis - therapy | Incidence | Aortic Valve Stenosis - epidemiology | Time Factors | Hospitalization - trends | Ontario - epidemiology | Sex Distribution | Female | Aged | Retrospective Studies | Population Surveillance - methods | Medical research | Mortality | Analysis | Aortic valve stenosis | Patient outcomes | Medicine, Experimental | Epidemiology | Health care | Elderly people | Intervention | Population growth | Stenosis | Cardiovascular disease | Hospitalization | Regression analysis | Patients | Clinical outcomes | Regression models | Morality | Coronary vessels | Aorta | Trends | Aortic valve | Elderly | Age | Geriatrics
Journal Article
American Heart Journal, ISSN 0002-8703, 11/2015, Volume 170, Issue 5, p. 1018
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.ahj.2015.06.027 Byline:...
Cardiology | Patient outcomes | Cardiac patients | Mortality | Risk factors | Cardiac arrest | Studies | Heart failure | Heart attacks | Hospitals | Comorbidity | Diuretics | Hospitalization | Health care access | Intubation | Cardiopulmonary resuscitation--CPR | Data bases
Cardiology | Patient outcomes | Cardiac patients | Mortality | Risk factors | Cardiac arrest | Studies | Heart failure | Heart attacks | Hospitals | Comorbidity | Diuretics | Hospitalization | Health care access | Intubation | Cardiopulmonary resuscitation--CPR | Data bases
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events...
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article